Xconomy Seattle

Seattle Genetics Pockets $11.5M

Luke Timmerman6/1/09

Seattle Genetics, the Bothell, WA-based developer of targeted antibody drugs, has raised another $11.5 million, according to a regulatory filing. The company received approval from existing shareholders sell more shares to Baker Brothers Life Sciences, an investment firm led by one of the firm’s directors, Felix Baker. The $11.5 million sale was a follow-on transaction from a $55 million offering the company pulled together in January.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.

Related Topics

Add Your Thoughts

You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted.
By clicking "Publish," you are agreeing to these Terms and Conditions.

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.